Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Bullboard Posts
Comment by biotechguy1on Jan 06, 2013 11:54am
134 Views
Post# 20803044

RE: hbiotechguy You left Out they have been Approa

RE: hbiotechguy You left Out they have been Approa

Simply stated 2 years for expedited review in Canada.   Most likely 6 months trial design....6 months to start centres and execute....1-2 years to achieve enrolment...1 year follow up and publish...another 1 - 2 years in the FDA or HPB for review and arppoval....yup 4-5 years.   Patent is 20....say patent is 3 years old 5 years to market....then that leaves 10 to 12 years of selling....not bashing just realistic...becasue of you i will be putting in stinks around 0.03 to 0.04 ( 50 K lots CIBC ) I will start in about 2 weeks...until then!!  GLTA

Bullboard Posts